Ру O’z Ўзб Eng
+998 71 228-06-96

+998 78 120-16-61

1002
not found
Кенгайтирилган қидирув

    JSC "Dori - Darmon" -
    we are trusted by all generations!

    not found

    Our mission is safe and affordable medicines

    not found
    not found
    not found
    not found

    Interactive Services

    Choose a service

    not found

    Search for medicine
    not found

    Vacancies
    not found

    Appeals statistics (IVR system)
    not found

    Appeal of individuals and legal entities

    News

    Follow the news of our company!

    View all
    not found

    Johnson & Johnson drops 136-year old logo and renames Janssen

    Johnson & Johnson has rebranded with a new logo and a new name for its Janssen pharmaceutical business one year after renaming its medical device business — and just weeks after spinning off its consumer health business. New Brunswick, New Jersey–based Johnson & Johnson (NYSE: JNJ) has replaced its 136-year-old logo — based on the signature of co-founder James Wood Johnson — with a “more modern logo and brighter red, keeping the iconic ampersand,” J&J CEO Joaquin Duato said today in a post on LinkedIn. The change is meant to call attention to J&J’s focus on innovative medicine and medtech, he said. The Janssen Pharmaceutical Cos. of Johnson & Johnson, meanwhile, is from now on going as Johnson & Johnson Innovative Medicine, “leading where medicine is going by developing breakthrough treatments, discovering new pathways and modalities, and expanding access so patients receive optimal care,” Duato said. Drug Discovery & Development: Johnson & Johnson pharma rebrand highlights innovation as a pillar to reinforce trust The move unites the pharma business with the Johnson & Johnson Medtech device business under a single name, he explained. “The power of a single, iconic name is tremendous,” Duato said. “Around the world, patients, doctors, nurses, and investors recognize Johnson & Johnson for our ability to deliver solutions for the toughest health challenges. Our exclusive focus in biology and medical technology allows us to innovate across the full spectrum of healthcare in ways no other company can — from cell therapy to AI-assisted robotic surgery.” Johnson & Johnson just last month completed the spinoff of its consumer health brand as a new independent company called Kenvue. Johnson & Johnson MedTech is the second-largest medtech company in the world, according to Medical Design & Outsourcing‘s latest Medtech Big 100 ranking. Janssen, meanwhile, is the world’s fourth-largest pharmaceutical company, per the Pharma 50 ranking by MDO sister publication Drug Discovery & Development. The Johnson & Johnson MedTech segment covers interventional solutions, orthopedics, surgery and vision, with brand names such as Biosense Webster, Cerenovus, DePuy Synthes, Ethicon, Acclarent and Acuvue. “The new Johnson & Johnson brand embodies our dynamic spirit while staying true to what has made J&J stand apart from others: our credo, our superpower of caring, and our relentless focus on transforming health for patients,” Johnson & Johnson EVP and Worldwide MedTech Chair Ashley McEvoy said on LinkedIn. “With the intersection of technology and biology fueling rapid innovation across our industry, this is an exciting time for Team MedTech.” Johnson & Johnson’s old logo dated back to 1887, making it one of the longest-running corporate logos in history.

    • 19 September, 12:01
    • Read more
    not found

    Uzbekistan and the United States are expanding the horizons of multifaceted cooperation

    On September 15 this year, on the eve of the visit of the President of the Republic of Uzbekistan Sh.M.Mirziyoyev to the United States of America, the Uzbekistan-US Business Forum was held in Washington, D.C. It was attended by the heads of key ministries and departments, industry associations, commercial banks and investment structures of the two countries, as well as heads of large US corporations engaged in the fields of ICT, engineering, agriculture, light industry, transport, banking and other areas.The speakers at the opening ceremony of the forum were Jamshid Khodjaev, Deputy Prime Minister of the Republic of Uzbekistan, Laziz Kudratov, Minister of Investment, Industry and Trade, Carolyn Lamm, Chairwoman of the Board, American-Uzbek Chamber of Commerce, Reta Jo Lewis, President and Chair of the Board of Directors, EXIM Bank of the USA, and John Mark Pommersheim, Deputy Assistant Secretary of State for Central Asia.The speeches emphasized rapid dynamics in the development of trade, economic and investment relations between our countries, which was facilitated by the political will of the leadership, as well as the constant interaction of governments and business circles.The Uzbek side presented key achievements in the development of the economy, trade, industry and improvement of the investment climate. In particular, along with other facts, the created mechanisms of free market and healthy competition, active support for entrepreneurship, infrastructural development, availability of energy resources, reduction of state participation in the economy and the launch of large-scale privatization processes were noted.Thanks to the reforms carried out, Uzbekistan has become an attractive investment destination, including for American business circles. Today, 300 US companies operate in Uzbekistan, which is more than twice as many as in 2017. Success stories are observed in various sectors, including automobile manufacturing - General Motors, agricultural machinery - John Deer, CNH, gas production - Air Products, agriculture – Silverleafe and others.At the same time, the most promising areas for the implementation of joint investment projects were identified, such as mining, chemical and energy industries, textile industry, agriculture, pharmaceuticals, electronics, information technology. There are great opportunities in the creation of joint ventures to manufacture products with high added value and their export to third countries.The importance of strengthenin business contacts between the two countries and readiness to provide comprehensive state support in the implementation of all joint projects and initiatives were emphasized.During the event, separate sessions were held on issues of global competition, ensuring the sustainability of supply chains, developing the business environment, stimulating innovation, strategic forecasting, privatization and financial and technical cooperation.The work of the business forum continued with "G2B" and "B2B" meetings between the heads of ministries, departments, industry associations and leading companies of Uzbekistan and the USA. The participants were able to profoundly discuss the creation of joint ventures and the conclusion of mutually beneficial trade agreements.As a result of the event, 12 documents were signed in the fields of energy, mechanical engineering, ICT, agriculture, financial, technical, scientific and technical cooperation, production of medical and pharmaceutical products.

    • 18 September, 15:47
    • Read more
    not found

    USAID Improving Medicines Quality and Safety in Uzbekistan

    The United States through its Agency for International Development (USAID), signed a new Memorandum of Understanding (MOU) with the Government of Uzbekistan towards expanding access to safe and quality tuberculosis and other medicines in Uzbekistan. During the first ever Uzbek-U.S. Health Forum, held in Tashkent, USAID Mission Director in Uzbekistan David Hoffman and Minister of Health Amrillo Inoyatov signed an MOU between USAID and the Center for Pharmaceutical Products Safety under the Ministry of Health to improve the quality of medicines in Uzbekistan and support the growth of the pharmaceutical industry of Uzbekistan. Director Hoffman stated that “USAID congratulates the Government of Uzbekistan for organizing the first ever Uzbek-U.S. Health Forum, opening the doors ever wider to partnerships and coordination between our two countries.” Through its Promoting the Quality of Medicines + activity implemented by U.S. Pharmacopeia, USAID works closely with national stakeholders and counterparts in Uzbekistan to sustainably strengthen the medicines quality assurance systems and improve access to quality-assured essential medical products for Uzbek citizens. Signed MOU sets the mutual understanding of both governments to continue progress towards together achieving the shared goals of improved health for all.

    • 11 September, 16:06
    • Read more
    not found

    Certain gut conditions may be early warning signs of Parkinson's disease

    Certain gut problems, such as constipation, difficulty swallowing, and irritable bowel syndrome (IBS), may be early warning signs of the neurological condition Parkinson's disease, suggests research published online in the journal Gut. Gastrointestinal symptoms are thought to precede the development of cerebrovascular disease, such as stroke or a brain aneurysm, or Alzheimer's disease, and it has been suggested (Braak's hypothesis) that gut conditions may precede the development of Parkinson's disease too. To test this hypothesis, the researchers used data from a U.S. nationwide medical record network (TriNetX) to compare 24,624 people who had been diagnosed with Parkinson's disease of unknown cause with those who had been diagnosed with other neurological conditions—Alzheimer's disease (19,046) or cerebrovascular disease (23,942)—-or with none of these (24,624; comparison group). Those with Parkinson's disease were matched with people in the other groups for age, sex, race and ethnicity, and length of diagnosis to compare the frequency of gut conditions included in their electronic health record for an average of 6 years before their Parkinson's disease diagnosis. The researchers then tested the same hypothesis, but in a different way, by dividing all the adults in the network who had been diagnosed with any of 18 gut conditions into separate groups—one for each condition of interest. People in these groups were matched with people without the particular gut condition and monitored via their medical records for 5 years to see how many of them developed Parkinson's disease or other neurological disorders. Both analyses indicated that four gut conditions were associated with a higher risk of a Parkinson's disease diagnosis. Specifically, gastroparesis (delayed stomach emptying), dysphagia (difficulty swallowing), and constipation were all associated with a more than doubling in risk of Parkinson's disease in the 5 years preceding the diagnosis, while IBS without diarrhea was associated with a 17% higher risk. Appendix removal, however, seemed to be protective, prompting questions about its potential role in the disease processes leading to Parkinson's disease, say the researchers. Neither inflammatory bowel disease nor vagotomy (removal of all or part of the vagus nerve to treat peptic ulcer) were associated with a heightened risk. Some other gut issues, including functional dyspepsia (burning sensation or fullness of the stomach with no obvious cause); IBS with diarrhea; and diarrhea plus fecal incontinence, were also more prevalent among people who developed Parkinson's disease. But these conditions were also more prevalent before the onset of Alzheimer's disease or cerebrovascular disease. This is an observational study, and as such, can't establish cause. The researchers also highlight several limitations to their findings, including that the monitoring period was relatively short and that the diagnostic information captured in electronic health records might have been incomplete. Nevertheless, they conclude, "This study is the first to establish substantial observational evidence that the clinical diagnosis of not only constipation, but also dysphagia, gastroparesis and irritable bowel syndrome without diarrhea might specifically predict the development of Parkinson's disease." They add, "These findings warrant alertness for [gastrointestinal] syndromes in patients at higher risk for Parkinson's disease and highlight the need for further investigation of [gastrointestinal] precedents in Alzheimer's disease and cerebrovascular disease."

    • 6 September, 15:01
    • Read more
    not found

    Novo Nordisk briefly overtakes LVMH as Europe's most valuable company

    Danish drugmaker Novo Nordisk unseated LVMH  as Europe's most valuable listed company on Friday, ending the French luxury group's 2-1/2 year-long reign at the top. LVMH, the world's biggest luxury retailer, has been hurt by growing concerns about the outlook for the Chinese economy. Novo is meanwhile riding a wave of demand for its highly effective diabetes and weight-loss drugs Ozempic and Wegovy, which has sent its earnings and shares to record highs. Its shares have risen around 17% since it announced on Aug. 8 that a large study had shown Wegovy also had a clear cardiovascular benefit, boosting the company's hopes of moving beyond its image as a lifestyle drug. As of Friday's close, Novo Nordisk had a market capitalisation of around $424.7 billion including unlisted stock, according to Refinitiv data and company disclosures of its share count. French-listed LVMH had a market cap of $420.1 billion, having been Europe's biggest listed company since February 2021 when it knocked consumer goods group Nestle off the top spot. 23-year timeline of Europe's largest company 23-year timeline of Europe's largest company Novo's share price has roughly tripled in the past three years while that of LVMH, home to fashion labels Louis Vuitton and Dior, has doubled. "Novo closing in on LVMH as Europe's biggest market cap stock is a reflection of Novo's recent product success while LVMH's recent trends have been more mixed," said Marcel Stotzel, co-portfolio manager of Fidelity European Fund and Fidelity European Trust.

    • 6 September, 09:06
    • Read more
    not found

    Over 600 dengue deaths recorded in Bangladesh

    The Bangladeshi government has confirmed another 16 deaths from dengue fever, bringing the total number of fatalities in the country since January to 634, the Directorate General of Health Services (DGHS) under the Ministry of Health reported on Sunday. The deaths includes 41 in September, 342 in August and 204 in July. On Sept. 1-3, 6,494 more dengue cases were recorded after 71,976 people were infected with the mosquito-borne disease last month, according to DGHS. A total of 2,608 fresh dengue cases, including 892 in Dhaka, were reported in the 24 hours till 8:00 a.m. local time Sunday, DGHS data showed. The total number of dengue fever cases reported since the start of January reached 130,302. Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash.

    • 5 September, 11:56
    • Read more
    not found

    Vitamin C and E supplements may make lung cancers grow faster

    Supplementing with antioxidants such as vitamins C and E could increase the formation of blood vessels within lung cancer tumours, helping them to grow bigger and spread, according to a study in mice. Taking antioxidant supplements such as vitamins C and E may cause lung cancers to grow bigger and spread by stimulating the formation of blood vessels within tumours, according to a study in mice. One researcher has stressed that people with the condition shouldn’t try to avoid these antioxidants in their diet, but getting more than they need via supplements could cause harm. Martin Bergö at the Karolinska Institute in Sweden and his colleagues previously found that supplementing with the antioxidants vitamin E and n-acetylcysteine caused lung cancers to spread in mice. To better understand how this might occur, Bergö and a new team of researchers studied mice with a murine-specific form of lung cancer and mice that had been implanted with human lung cancer cells. They supplemented the mice’s water with vitamin C, which the animals naturally produce, and vitamin E and n-acetylcysteine, which they get from their diet. These supplements were administered at increasing doses, all of which caused the mice’s levels of these antioxidants to exceed what was necessary. “Today in society, you have a lot of people who eat healthily, they have some supplements, and then they may have a ginger shot and a smoothie,” says Bergö. “If you do all that, you could end up with the levels of doses that we’re talking about.”

    • 4 September, 10:28
    • Read more
    not found

    Working nights leads to a higher chance of memory loss, experts warn

    People on the night shift may run a greater risk of memory loss compared to those takin’ care of business during the day, a new study has shown. Researchers at York University in Canada found that those working shifts outside the average 9 a.m. to 5 p.m. schedule were more prone to suffer from cognitive impairments, such as inability to think clearly, brain deterioration and behavioral changes. The study, which gathered data on 47,811 adults and analyzed self-reported employment information alongside the results of cognitive function tests, was published this week in the open-access journal PLOS ONE. “Findings suggest a potential link between shift work exposure and cognitive function impairment,” the experts concluded. Working nights could lead to memory loss in middle-aged and older adults as those working late have 79% higher rates of cognitive impairment. And while the overnighters may have been more likely to suffer from issues with memory, those on more regular hours were more likely to struggle with the ability to manage their own thoughts, emotions and actions. Nearly one in five individuals (21%) are likely to engage in shift work during their careers. The experts suggest that the disruption to a person’s circadian rhythm caused by shift work is likely causing these detrimental impacts to people’s cognitive function, especially in middle-aged and older adults. Every cell in the body operates on a circadian clock, an internally driven 24-hour rhythm that often runs longer than 24 hours. It resets every day by the sun’s cycle but can be disrupted by too much or too little sunlight exposure — a common issue for shift workers. A person’s circadian clock sets the timing for many important bodily functions including sleep cycles, hormonal activity, body temperature rhythm, eating and digesting.  Every adult should be tucking themselves in for at least seven hours a night, according to the Centers for Disease Control and Prevention. It’s estimated that nearly half of Americans are sleep-deprived. Offsetting the body’s circadian rhythm has been associated with a higher risk of a multitude of health issues including chronic diseases, depression, obesity, Type 2 diabetes, cardiovascular problems and headache disorders.

    • 29 August, 19:53
    • Read more
    not found

    The Global Pharmaceutical Leaders’ Club invites you for the 4th Eurasian Pharmaceutical Summit, which will be held with the support of the Pharmaceutical Industry Development Agency of the Ministry of Investment

    The Global Pharmaceutical Leaders’ Club invites you for the 4th Eurasian Pharmaceutical Summit, which will be held with the support of the Pharmaceutical Industry Development Agency of the Ministry of Investment, Industry and Trade of the Republic of Uzbekistan. The summit will be held in a hybrid format on the 26th - 28th September with an offline part in Samarkand. This is the only conference that comprehensively covers the development trends in the pharmaceutical markets of the countries in Central Asia, the Caucasus and Eastern Europe. In an offline format the summit will bring together 250+ leading pharmaceutical market professionals from 10 countries and 100+ speakers from regulatory authorities, pharmaceutical manufacturing companies, distributors and pharmacy chains. The summit programme includes 20+ sessions, where the issues of market access, registration of pharmaceutical drugs, public procurement, labelling, pricing, sales, marketing and production of medicines will be discussed. There will be round tables with regulators and one-to-one meetings with top managers of leading pharmaceutical companies. For the first time, within the framework of the summit, visits to pharmaceutical drug distribution centres and manufacturing enterprises in Samarkand will be organised. As a part of the Eurasian Pharmaceutical Summit, the Eurasian Pharma Awards competition will be held for the 4th time. International and local pharmaceutical drug manufacturers, distributors and pharmacy chains are invited to participate. Details about the summit are on the website: https://eurasianpharmasummit.com/en/. 

    • 16 August, 08:56
    • Read more
    not found

    Drug prices reach new high — in the millions

    A new era of expensive drugs has arrived: medicines priced in the millions of dollars a patient. U.S. or European health regulators have approved four new products intended as one-time treatments for rare genetic diseases that carry list prices of at least $2 million a patient. The most recent one approved in the U.S. set a price record: $3.5 million for CSL Ltd.’s Hemgenix, a treatment for the blood disorder hemophilia B. The price tags mark a new high for medicines, which drugmakers were once reluctant to charge more than six figures for but whose prices have been heading upward. The companies say the cost reflects the drugs’ potential to help patients in a single dose, but paying for it could challenge patients and health insurers. Most of the multimillion-dollar treatments are gene therapies, a groundbreaking type of treatment that involves injecting a functional gene into a person to correct a faulty, disease-causing one. Bluebird’s Skysona gene therapy for a rare neurological disease affecting children costs $3 million, while its Zynteglo for an inherited blood disorder is priced at $2.8 million. Novartis AG’s Zolgensma gene therapy treating a muscle-wasting condition costs $2.1 million. Some of the new therapies could produce long-term savings, the companies say,by sparing patients from having to take older treatments repeatedly for the rest of their lives. McKinsey & Co. estimates that about 30 new gene therapies could be introduced in 2024 alone.

    • 15 August, 09:02
    • Read more

    Gallery

    View all
    not found
    20.10.2022
    not found
    20.10.2022
    not found
    14.10.2022
    not found
    11.09.2022
    not found
    30.08.2022
    not found
    06.08.2022
    not found
    06.08.2022
    not found
    06.08.2022
    not found
    12.07.2022

    Videagallery

    View all
    not found

    30 August, 16:02
    not found

    On August 16-17 this year, the health ministers of the Organization of Turkic States will meet in Samarkand.

    15 August, 14:57
    not found

    Noqonuniy dori ishlab chiqarayotgan tsex faoliyati toʻxtatildi

    26 June, 11:03
    not found

    Italiyada qadimiy dorixona qayta tiklandi

    9 June, 14:37
    not found

    "Sogʼliqni saqlash – TIHE 2023” koʼrgazmasidan lavhalar

    17 April, 16:38
    not found

    OAV biz haqimizda. "Assalom, O`zbekiston" dasturi 01.04.2023

    5 April, 10:15
    not found

    “Dori-Darmon” aksiyadorlik kompaniyasi jamoasining sumalak saylidan esdalik lavhalar

    25 March, 10:09
    not found

    IIV:Samarqandda kuchli taʼsir qiluvchi "Regapen" psixotrop moddalarini sotayotgan dorixona rahbari qoʼlga olindi

    28 February, 12:20
    not found

    Bepul dori vositalari

    16 February, 11:38
    not found

    Qadoqdan ochilgan dorilarni saqlash muddati

    13 February, 11:57
    Stop corruption!

    Hotline

    (+99878) 120-16-61

    Interactive map

    Services

    not found

    ООО «INTEGRA DD»

    In 2010 in Samarkand, in order to implement a project to organize the production of injectable drugs in accordance with international standards of GMP, the company “InegtraDD” LLC was established. The total area of the plant with developed infrastructure is 11,200.0 sq.m.

    Go to website
    not found

    ООО «Dori-Darmon HCP»

    In 2007 “Dori Darmon HCP” LLC was established, represented in Uzbekistan under the brand name “Elysee Parfumerie”. The main activity is the retail sale of luxury cosmetics and perfumes.

    Go to website
    not found

    ООО «DD General Insurance»

    In 2011, “DD General Insurance” JSC was founded, the main task of which is to provide reliable insurance protection of property interests of legal entities and individuals. Today the company has its own solid customer base of numerous types of voluntary insurance. At the end of 2021 rating agency “Standard and Sensitive Ratings” assigned to the company solvency and reliability rating according to the national scale “uzA++” (the highest) with the “Stable” outlook which means that the company has an outstanding ability to fulfill its obligations and claims of policy holders in time and in full. In the future it is planned to develop the direction of compulsory health insurance.

    Go to website
    not found

    ООО «Dori-Darmon Garant»

    In 2005 an order was signed on the establishment of “Dori-Darmon Garant” LLC, with a customs warehouse with a total area of 2000 square meters, which provides modern storage service for imported medicines and medical devices. In 2012, for the first time in Uzbekistan was implemented a large-scale project of the concept “Smart warehouse”, which uses automated storage and logistics systems.

    Go to website
    not found

    ООО «Дори-Дармон Инвест»

    In 2004, “Dori Darmon Invest” LLC was organized, specializing in research of the pharmaceutical market of Uzbekistan, providing services for the registration of medicines for manufacturers who do not have their offices in the country.

    Go to website

    Partners

    not found
    not found
    not found
    not found

    State resources

    not found

    E-Government Projects Management Center
    not found

    Open Data Portal of the Republic of Uzbekistan
    not found

    National database of legislation jf the Republic of Uzbekistan
    not found

    Виртуальная приёмная Президента Республики Узбекистан
    not found

    Правительственный портал Республики Узбекистан
    not found

    Action strategy on five priority areas of development of the Republic of Uzbekistan in 2017-2021

    Questions

    and answers

    You can contact us with numbers +998 71 228-06-96 and 1002

    344 raw materials and materials, medical products and packaging materials, imported for the purpose of drug preparation in the pharmacy, used for feeding laboratory animals, pre-clinical research and drug production (including drug preparation) that are not produced in the Republic of Uzbekistan, will be exempted from customs duties until January 1st 2025.

    Вы можете связаться с нами по телефону +998 71 228-06-96 или же по короткому номеру 1002

    First of all, it is recommended to use antiseptics to disinfect hands. Hydrogen peroxide and furacilin are mainly antibacterial agents. Since antiseptic agents contain 70 percent ethyl alcohol, they have the ability to destroy the shells of viruses.

    not found

    Have questions?
    Let us help!

    Нажмите на кнопку ниже, чтобы прослушать текст Powered by GSpeech